CF PharmTech, Inc. disclosed that it bought back 11,500 H-shares on 08 May 2026 through on-exchange transactions, paying a total of HKD 0.25 million at prices between HKD 21.58 and HKD 21.90 per share (volume-weighted average: HKD 21.75).

The repurchase reduced the company’s outstanding share count (excluding treasury shares) by 0.0038 % to 301.52 million shares. Treasury holdings increased from 687,500 to 699,000 shares, while total issued shares remained unchanged at 302.22 million.

The buyback forms part of a mandate approved on 16 December 2025 that authorises repurchases of up to 30.22 million shares. To date, 699,000 shares—equivalent to 0.2313 % of the issued share base at the time of the mandate—have been repurchased under this authority.

Under Hong Kong listing rules, CF PharmTech is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, lasting until 07 June 2026.